Vaxcyte, Inc. (NASDAQ:PCVX) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 108,389 shares of the company's stock after acquiring an additional 29,442 shares during the period. Russell Investments Group Ltd. owned about 0.09% of Vaxcyte worth $8,873,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Envestnet Asset Management Inc. raised its holdings in Vaxcyte by 12.5% in the 4th quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company's stock worth $4,509,000 after purchasing an additional 6,121 shares during the period. Wells Fargo & Company MN increased its position in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after buying an additional 25,257 shares in the last quarter. Headlands Technologies LLC raised its stake in shares of Vaxcyte by 41.9% during the 4th quarter. Headlands Technologies LLC now owns 39,417 shares of the company's stock worth $3,227,000 after buying an additional 11,635 shares during the period. Geode Capital Management LLC lifted its position in shares of Vaxcyte by 3.8% during the 4th quarter. Geode Capital Management LLC now owns 2,802,888 shares of the company's stock valued at $229,495,000 after buying an additional 102,106 shares in the last quarter. Finally, National Bank of Canada FI acquired a new stake in Vaxcyte in the 4th quarter valued at $41,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Vaxcyte

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the sale, the director now directly owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew Guggenhime sold 8,000 shares of the company's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the completion of the transaction, the chief financial officer now owns 109,491 shares in the company, valued at approximately $9,472,066.41. This represents a 6.81 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock worth $3,170,738 in the last 90 days. Insiders own 3.10% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

PCVX has been the topic of several recent analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a report on Tuesday, April 8th. Bank of America lowered their price objective on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. The Goldman Sachs Group reduced their price objective on Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. Finally, Guggenheim reaffirmed a "buy" rating and set a $160.00 target price on shares of Vaxcyte in a research note on Wednesday, March 12th. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded down $1.81 during trading on Tuesday, hitting $30.23. 2,545,007 shares of the company were exchanged, compared to its average volume of 1,206,542. The company has a fifty day moving average price of $65.25 and a 200-day moving average price of $84.98. The firm has a market capitalization of $3.89 billion, a PE ratio of -6.57 and a beta of 1.26. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.14. Research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.